402 related articles for article (PubMed ID: 26957834)
1. Updates on the Clinical Trials in Diabetic Macular Edema.
Demirel S; Argo C; Agarwal A; Parriott J; Sepah YJ; Do DV; Nguyen QD
Middle East Afr J Ophthalmol; 2016; 23(1):3-12. PubMed ID: 26957834
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
3. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
4. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
Cai S; Bressler NM
Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
7. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
Wood EH; Karth PA; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
[TBL] [Abstract][Full Text] [Related]
8. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
[TBL] [Abstract][Full Text] [Related]
9. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
[No Abstract] [Full Text] [Related]
10. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM; Ciulla TA
Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
[TBL] [Abstract][Full Text] [Related]
11. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
[No Abstract] [Full Text] [Related]
12. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
Ehlers JP; Yeh S; Maguire MG; Smith JR; Mruthyunjaya P; Jain N; Kim LA; Weng CY; Flaxel CJ; Schoenberger SD; Kim SJ
Ophthalmology; 2022 Jan; 129(1):88-99. PubMed ID: 34446301
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
14. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
Bandello F; Cicinelli MV; Parodi MB
Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
[TBL] [Abstract][Full Text] [Related]
17. Determinants in Initial Treatment Choice for Diabetic Macular Edema.
VanderBeek BL; Scavelli K; Yu Y
Ophthalmol Retina; 2020 Jan; 4(1):41-48. PubMed ID: 31345726
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
Xiao K; Li FZ; Liang SZ; Wang J; Qian C; Wan GM
Ann Pharmacother; 2020 Aug; 54(8):750-756. PubMed ID: 32005079
[No Abstract] [Full Text] [Related]
19. The Short-term Effect of a Single Lapse in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice.
Yalamanchili SP; Maatouk CM; Enwere DU; Conti TF; Hom GL; Briskin IN; Greenlee TE; Babiuch AS; Singh RP
Am J Ophthalmol; 2020 Nov; 219():215-221. PubMed ID: 32640254
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]